Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Fish Biol ; 104(1): 310-314, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37721715

ABSTRACT

Identifying the factors that influence the citation of articles helps authors improve the impact and reach of their research. Analysis of publications in the Journal of Fish Biology between 2008 and 2021 revealed that variables such as the number of keywords, abstract length, number of authors, and page length were associated with higher impact papers. These trends applied to both review and regular papers. These findings suggest that papers that are more informative, have higher numbers of authors, and have more keywords are more likely to be cited. Adoption of some simple "best-practice" behaviors can improve the likelihood that a paper is cited.


Subject(s)
Fishes , Journal Impact Factor , Animals , Biology
2.
J Urol ; 159(1): 149-53, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9400459

ABSTRACT

PURPOSE: A pilot study of the antiandrogen bicalutamide at 150 mg. a day for androgen independent prostate cancer was performed. This study was based on the possibility that androgen independent cases might display responses to additional hormonal agents. MATERIALS AND METHODS: The study included 31 androgen independent cases with an increasing prostate specific antigen (PSA) and progressive disease. PSA measurements were used as the primary method of assessing response. However, PSA decline was also correlated with clinical status. RESULTS: Seven patients demonstrated PSA declines of greater than 50% for 2 months or more, for an overall response rate of 22.5%. Responses were observed almost exclusively in patients treated with long-term flutamide as part of a complete androgen blockade regimen (43% response rate) in contrast to patients treated with androgen deprivation without flutamide (6% response rate). Of the 7 PSA responding patients bicalutamide resulted in a significant improvement in performance status and a decrease in analgesic requirement in 4 and 3 remained asymptomatic. Bicalutamide at 150 mg. a day was well tolerated, with the most frequent side effect being mild exacerbation of hot flashes. CONCLUSIONS: Bicalutamide at this dose is modestly effective for some patients with androgen independent prostate cancer, particularly for those previously treated with long-term flutamide. This study indicates that previous antiandrogen therapy alters the response to subsequent hormonal agents.


Subject(s)
Androgen Antagonists/therapeutic use , Anilides/therapeutic use , Antineoplastic Agents/therapeutic use , Prostatic Neoplasms/drug therapy , Aged , Aged, 80 and over , Antineoplastic Agents, Hormonal/therapeutic use , Flutamide/therapeutic use , Humans , Male , Middle Aged , Nitriles , Pilot Projects , Prostate-Specific Antigen/blood , Prostatic Neoplasms/blood , Tosyl Compounds
3.
Clin Cancer Res ; 3(8): 1383-8, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9815822

ABSTRACT

Mutations in the androgen receptor (AR), that alter steroid hormone specificity have been identified in a series of androgen-independent prostate cancers. To address the functional properties of these mutant ARs that may have contributed to their selection in vivo, responses to a series of steroid hormones and antiandrogens were assessed. CV-1 cells were cotransfected with wild-type or mutant ARs and a luciferase reporter plasmid regulated by an androgen-responsive element. Dose-response curves were analyzed for 5alpha-dihydrotestosterone, the most active androgen in normal prostate, and androstenedione, a major androgen derived from the adrenals. Although the mutant ARs responded to both of these steroids, the responses were equivalent to or less than the wild-type AR. In contrast, responses to flutamide, a competitive antagonist of the wild-type AR, were markedly increased by three of the mutations. Similar responses were observed with a second antiandrogen, nilutamide. Bicalutamide, another antiandrogen related to flutamide, remained an antagonist for these mutant ARs. Finally, flutamide was observed to be a weak partial agonist of the wild-type AR in this system. These results indicate that flutamide used in conjunction with androgen ablation therapy for prostate cancer may select for tumor cells with flutamide-inducible ARs.


Subject(s)
Androgen Antagonists/pharmacology , Androgens/pharmacology , Imidazolidines , Point Mutation , Prostatic Neoplasms/genetics , Receptors, Androgen/genetics , Amino Acid Substitution , Androstenedione/pharmacology , Animals , Cell Line , Dihydrotestosterone/pharmacology , Estradiol/pharmacology , Flutamide/analogs & derivatives , Flutamide/pharmacology , Genes, Reporter , Imidazoles/pharmacology , Luciferases/genetics , Male , Progesterone/pharmacology , Prostatic Neoplasms/metabolism , Receptors, Androgen/biosynthesis , Receptors, Androgen/physiology , Recombinant Fusion Proteins/biosynthesis , Transfection , beta-Galactosidase/genetics
4.
Oncology ; 45(3): 210-3, 1988.
Article in English | MEDLINE | ID: mdl-3368197

ABSTRACT

Canine transmissible venereal sarcoma (CTVS) is a contagious neoplasm which regresses spontaneously in adult dogs but metastasizes and kills puppies transplanted with the neoplasm at a very young age. Immunofluorescence studies showed that 30 +/- 14% of cells from steady-state and 22 +/- 7% of cells from regressing tumors had membrane-bound antibodies which could be eluted out with warm washes at 24 degrees C, whereas the cells from progressor tumors had very little such antibody (6 +/- 6%). Time-course kinetics of anti-CTVS antibodies in the serum of tumor-bearing dogs did not correlate well with tumor volume, however, the presence of such antibodies in adult dogs (47 +/- 13%) but absence (0%) in the puppies with tumor metastasis suggested the importance of antibodies in resistance to metastasis.


Subject(s)
Antibodies, Neoplasm/immunology , Sarcoma, Experimental/immunology , Animals , Antigens, Neoplasm/immunology , Dogs , Immune Sera , Immunity, Innate , Isoantigens/immunology , Neoplasm Metastasis/immunology , Neoplasm Transplantation , Remission, Spontaneous , Sarcoma, Experimental/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...